• Alias: AMG 102
    • A fully human IgG2 monoclonal antibody that binds to and neutralizes the human hepatocyte growth factor, HGF, preventing the binding to its receptor, MET
    • Currently in phase 2 clinical trials for gliomas, NSCLC, and GI cancers
    • Recommended dose: 10 to 20 mg/kg IV every 21 days with chemotherapy
    • Half-life: 14 to 22 days
    • Common side effects: Fatigue, constipation, nausea/vomiting, anorexia, myalgia, hypotension, hypoxia, dyspnea, GI hemorrhage, colonic fistula
    (Gordon et al., 2010)
    Other topics in Targeted and Immunotherapy Agents